Clinical Trial

A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Name: A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer — clinical trial record (NCT06147570)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

HS-10365 is a small molecular, oral potent, selective RET inhibitor. The purpose of this study is to investigate the efficacy and safety of HS-10365 in Chinese advanced RET fusion-positive non-small cell lung cancer patients without any systemic therapy.

Trial Details

NCT Number	NCT06147570
Lead Sponsor	Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions	Nonsmall Cell Lung Cancer
Enrollment	62 participants
Start Date	2023-09-25
Primary Completion	2027-08-31 (estimated)
Study Completion	2028-08-31 (estimated)
Updated on ClinicalTrials.gov	2023-11-27